Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Inflammatory myofibroblastic tumor of the upper airways harboring a new TRAF3-ALK fusion transcript.
  • +6
  • Valentina Di Ruscio,
  • Angela Mastronuzzi,
  • Ida Russo,
  • Marianna Neri,
  • Alessandra Stracuzzi,
  • Isabella Giovannoni,
  • Maria Luisa Tropiano,
  • Maria Antonietta De Ioris,
  • Giuseppe Maria Milano
Valentina Di Ruscio
Bambino Gesu Pediatric Hospital
Author Profile
Angela Mastronuzzi
Ospedale Pediatrico Bambino Gesù
Author Profile
Ida Russo
Ospedale Pediatrico Bambino Gesu
Author Profile
Marianna Neri
Azienda ospedaliera Annunziata
Author Profile
Alessandra Stracuzzi
Bambino Gesu Pediatric Hospital
Author Profile
Isabella Giovannoni
Children’s Hospital Bambino Gesù
Author Profile
Maria Luisa Tropiano
Bambino Gesu Pediatric Hospital
Author Profile
Maria Antonietta De Ioris
Ospedale Pediatrico Bambino Gesù
Author Profile
Giuseppe Maria Milano
Bambino Gesu Pediatric Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Inflammatory myofibroblastic tumor (IMT) is a rare disease that mainly involves the lung and the abdomen with an intermediate clinical course but a recurrence rate between 15-30%. Radical surgery represents the golden standard of treatment, while chemotherapy and radiotherapy are considered for unresectable lesions. The identification of ALK translocations in IMT opened the option for the use of target therapies1. Indeed, the ALK inhibitors have changed the treatment approach for aggressive lesions, improving the prognosis. Intraluminal upper way IMT is extremely rare and represents a medical challenge. We reported an endotracheal IMT case presenting a before unknown TRAF3-ALK fusion transcript.